psoriasis drug

Pharmaceutical pipeline: Top 4 conditions to watch
Pharmaceutical pipeline: Top 4 conditions to watchAlthough drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.
A new class steps forwardPhosphodiesterase (PDE) inhibitors including apremilast and crisaborole ointment may provide safer alternatives than traditional steroid-sparing agents for psoriasis and atopic dermatitis. Side effects of apremilast may include GI symptoms, weight loss and depression, and taking apremilast with anti-seizure drugs or rifampin lowers apremilast blood levels, Apremilast is being studied in inflammatory bowel disease, Behcet's disease and pediatric psoriasis, and may have a place in the treatment of hidradenitis suppurativa (HS).
FDA approves etanercept for pediatric psoriasisThe US Food and Drug Administration (FDA) approval of etanercept for treatment of children with moderate to severe plaque psoriasis will revolutionize the management of psoriasis in children.
6 facts to know about the new psoriasis drugFDA approved ixekizumab (Taltz, Eli Lilly and Co.) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.